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Since the first human orthotopic liver trans-
plantation on March 1, 1963, 283 patients with 
various liver diseases had received liver homografts 
at the University of Colorado and the University of 
Pittsburgh by February 28, 1983. During this 20-
year period many scientific observations and surgi-
cal technical improvements were reported from the 
experience in liver transplantation. ls However, sig-
nificant improvement of survival after liver trans-
plantation had to await the discovery and clinical 
use of cyclosporine, a potent immunosuppressive 
agent derived from the fungi Cyclidrocarpon lud-
dum and Trichoderma polysporum.1.2·5.7.21.26 
We report here the current status of hepatic 
transplantation, mainly focusing on the 100 consec-
utive liver recipients who were treated with cyclo-
sporine and low-dose prednisone since March, 1980. 
RECIPIENT SELECTION 
Age 
Although a 7 -month-old baby with neonatal 
hepatitis and a 57-year-old man with hepatoma in a 
cirrhotic liver are alive 16 months and 12 months, 
respectively. after liver transplantation, it is desir-
able that the recipient be between 1 year and 50 
years of age. Surgical technical complications are 
more common in very small infants, and cardiopul-
monary complications are frequent in elderly 
recipients. 
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Infections 
Infection is the most common cause of death 
after liver transplantation. 6,13,14,21.24.25 Significant 
pulmonary, urinary tract, and biliary tract infections 
must have been eradicated before transplantation. 
Spontaneous peritonitis is common in cirrhotic pa-
tients. 
Virus infection is aggravated by immunosup-
pression therapy. Hepatitis B virus, documented by 
HBsAg or e-antigen, persists or reappears after a 
short period and leads to chronic aggressive hepatitis 
of the graft.8,21 Nevertheless, we are still accepting 
candidates with positive HBsAg, but are attempting 
to modulate the course of viral hepatitis by hyper-
immune globulin, vaccination, and/or interferon 
therapy. 
Malignancy 
Malignant tumors grow more aggressively 
under immunosuppression therapy.18 Malignancy 
outside the liver must be proved to be cured before 
consideration of transplantation. Primary malig-
nancy of the liver is one of the indications for liver 
transplantation, but the incidence of recurrence has 
been very high if the recipients live long enough.3,6, 
10.21.24,25 Metastatic tumor to the liver is not an 
indication for liver transplantation. 
Other Conditions 
Severe mental retardation, uncontrolled psychi-
atric disorders, alcoholism, and drug abuse before 
rehabilitation create unsuitable conditions for trans-
plantation. Uncomplicated diabetes mellitus is a 
relative contraindication for liver transplantation. 
Diabetes has been treated by simultaneous pancreas 
transplantation.4 Disabling cardiopulmonary dis-
eases are contraindications for liver transplant, 
unless heart and/or lung transplantation is con-
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sidered at the same time. However, such a drastic 
procedure has never been done. Renal failure from 
hepatorenal syndrome is not a contraindication. I I 
Active gastrointestinal bleeding should be controlled 
before transplantation. Deep hepatic coma (grade 4) 
with severe brain edema may progress to herniation 
and brain death before the graft liver reverses the 
pathology. 
Timing 
Many of the early deaths after transplantation 
have been attributable to the poor condition of the 
recipients. The assessment of timing of transplant 
for acute liver failure is much more difficult than 
that of chronic liver failure. Moribund patients 
cannot be saved by liver transplantation. Trans-
plantation too late in the course of either chronic or 
acute disease is as unjustified as transplantation too 
early. I f the patient is chronically hospitalized or 
house-bound, or the patient cannot conduct a 
reasonably satisfying life because of liver disease, 
liver transplantation may be offered. 
RECIPIENT WORK-UP 
By the time candidates are brought into the 
transplant center for final evaluation, they are often 
too ill to undergo extensive investigation of their ill-
nesses. Mild sedation for endoscopy has led to 
hepatic encephalopathy and/or aspiration pneu-
monia, and prolonged starvation for tests or con-
trast media for radiologic tests has introduced frank 
renal failure to the candidates who have marginal 
hepatic and renal function. Most of the candidates 
with chronic liver disease have already had extensive 
work-up for their disease. Careful review of past 
medical records is often all that is necessary. 
A guideline of recipient work-up is shown in 
Table 1. If the etiology of the liver disease has been 
established, it is excessive to check all the tests listed 
in Table 1. 
Noninvasive radiographic procedures, such as 
ultrasonography and computed tomography, are 
quite useful in assessing the anatomy of and sur-
rounding the liver, and they decrease the need of 
invasive angiography. Patency and size of the portal 
vein and the inferior vena cava can be determined 
quite accurately by ultrasonography. If these are 
not identified by ultrasonography and/or computed 
tomography (CT), angiography is indicated. The 
size of the liver and the extent of any tumor can be 
accurately determined by CT and ultrasonography. 
If the biliary ducts are shown to be dilated by ultra-
sonography and/or CT, endoscopic retrograde 
cholangiography or trans hepatic needle cholangiog-
raphy may be indicated. 
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TABLE 1. A Guideline of Recipient Work-Up· 
I. Complete history and physical examination. 
Review of past medical records. 
Body weight, height, and abdominal girth. 
Vital signs, intake and output, nutritional evaluation. 
2. Urinalysis and occult stool blood. 
3. Complete blood count, platelet count, serum sodium, potas-
sium, chloride, carbon dioxide, calcium, phosphorous, 
magnesium, blood urea nitrogen, creatinine. total protein/ 
albumin, total bilirubin/direct, SGOT, SGPT. alkaline 
phosphatase. gamma glutamyl trans peptide, lactate dehydro-
genase. amylase, glucose and ammonia. prothrombin time 
and partial thromboplastin time, blood gas. 
4. Cultures (such as blood, urine, sputum. ascites). 
5. Blood typing and antibody screen. 
Hepatitis A and B screen. 
Coagulation profile. 
HLA-A. B, and DR typing and cytotoxic antibody screen. 
6. Ceruloplasmin. alpha-I-antitrypsin level and phenotype. anti-
mitochondrial antibody. antinuclear antibody, antismooth 
muscle antibody, serum iron, ferritin. Lupus erythematosus 
preparation. Serum protein electrophoresis. quantitative im-
munoglobulins. 
7. Antiviral antibody titers. 
8. Chest x-ray. Ultrasonography. computed tomography (CT) 
scan, cholangiography, angiography, upper and lower gastro-
intestinal series. 
9. Endoscopy (panendoscopy. endoscopic retrograde cholangio-
pancreatography. colonoscopy). 
10. Ophthalmologic examination. 
II. Neuropsychiatric evaluation, brain CT scan, electroencepha-
logram. 
12. Social worker evaluation. 
13. Freeze serum and plasma for future investigation. 
"Limit the tests to absolute minimum for proper diagnosis and 
treatment. 
Cultures of all sources are indicated even in the 
absence of fever, leukocytosis, or any clinical sign 
of infection. 
DONOR-RECIPIENT MATCHING 
Liver Size 
Matching the size of donor and recIpient is 
quite important in order to avoid technical diffi-
culties in surgery. With the shrunken livers of cir-
rhosis, a smaller donor than recipient is usually 
desirable. 
ABO Blood Group 
In organ transplantation group 0 patients can 
be considered universal donors and group AB pa-
tients are universal recipients. 17 Although the liver 
graft is resistant to hyperacute rejection and ABO 
blood group incompatible grafts have functioned 
for years,2l,24,2S this practice should be limited to 
absolutely life-threatening situations. 
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T-Warm Cross-Match 
Liver transplantation has been performed 
against the recipient antidonor T -warm antibodies, 
which cause hyperacute rejection of kidney homo-
grafts.9,21,24,2S There has been no hyperacute rejec-
tion of liver homografts to our knowledge. Graft 
survival of positive T -warm cross-match donors has 
been about the same as that of negative cross-match 
donors. A positive T -warm cross-match is not a 
contraindication to liver grafting. 
HLA Typing 
The time constraints of liver preservation and 
the urgent recipient need preclude efforts at tissue 
matching at the A, B, and DR (D-related) histo-
compatibility loci. 
DONOR OPERATION 
The satisfactory early function of transplanted 
whole organs is largely dependent upon procurement 
techniques that minimize ischemic injury. The 
amount of ischemia, warm or cold, that an organ 
can tolerate and still provide life-sustaining function 
following transplantation is different for each organ 
system. When compared with livers and hearts, 
kidneys are relatively more tolerant of both warm 
and cold ischemia. Using the techniques to be out-
lined, the incidence of first week dialysis in patients 
receiving renal allografts procured in combination 
with livers or hearts or both is less than 10070. 15,16 
In addition satisfactory livers or hearts usually can 
be obtained unless there has been faulty donor 
selection. 
Technique 
A long midline abdominal inCISIon combined 
with a midline sternotomy provides excellent expo-
sure. 1S,16 After gross inspection of the organ to 
determine suitability, the initial dissection is done 
by the liver team. Anomalies of hepatic arterial 
supply are identified and preserved. The celiac axis 
(and superior mesenteric artery if it has a hepatic 
branch) is dissected back to the origin from the 
aorta, and all nonhepatic branches are ligated and 
divided. The hilar dissection is completed by divid-
ing the common bile duct as close to the duodenum 
as possible, followed by isolation of the portal vein. 
The pancreas can be divided between mass ligatures 
to gain better exposure of the splenic and superior 
mesenteric veins. Attention is then turned to a com-
plete division of all of the supporting ligaments of 
the liver. The suprahepatic vena cava is encircled. 
This maneuver is facilitated by individual ligation 
of the phrenic veins. 
Once the hepatic dissection is completed, the 
nephrectomy team proceeds to mobilize both kid-
neys and ureters. 
The next step involves cannulation of the distal 
aorta and vena cava at the iliac vessels and place-
ment of a catheter into the splenic vein. 
The most critical step at this point for proper 
preservation of the liver is to begin a precooling 
stage by infusion of cold (4°C) lactated Ringer's 
solution into the portal venous system via the 
splenic vein cannula. The superior mesenteric vein 
and artery are ligated simultaneously beginning with 
this infusion. Because arterial circulation is intact, 
this provides nonischemic core cooling to the large 
mass of hepatic tissue. It has the added advantage 
of cooling the entire cadaver, thus further protect-
ing the other organs. If the heart is to be procured, 
the cardiac team can complete its dissection at this 
time. 
The proper sequencing of organ removal re-
quires cooperation among the various teams. 
Hepatic precooling is complete when several liters 
have been infused and donor temperature has 
reached 28 to 30°C. If the heart is to be taken, it is 
removed first. The abdominal aorta is clamped at 
the diaphragm and the cannula in the distal aorta 
opened as soon as circulatory arrest is effected by 
the cardiectomist. Simultaneously, the vena cava 
cannula is opened and allowed to drain freely. The 
portal vein infusion is changed from an extracellu-
lar (lactated Ringer's) to an intracellular (modified 
Collins solution) composition for a final flush of 
500 to 1500 ml. The composition of the aortic flush 
solution is the choice of the nephrectomy team, but 
most often is Collins solution or one of its modifi-
cations. The advantage of this in situ flush of the 
kidneys is the complete elimination of warm 
ischemia. 
Once removed, the organs are placed in an ice 
bath and inspected. They are stored and transported 
in ice slush, although kidneys may also be preserved 
with pulsatile pump perfusion. 
At the present time, hepatic allografts for 
clinical use are transplanted as soon as possible 
following removal. Cold ischemia up to 12 hours 
has been tolerated, but an effort is made to keep 
this time under 5 or 6 hours. 
RECIPIENT OPERATION 
The principles of recipient hepatectomy and 
orthotopic liver transplantation were established 15 
years ago lS and have not been changed. with the 
exception of minor modifications.21 ,24,2S Originally, 
t 
:1 
'I 
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splenectomy was performed at the time of trans-
plantation if it had not been carried out at an earlier 
time. One of the reasons was that with the hyper-
splenism and leukopenia of portal hypertension an 
adequate amount of azathioprine could not be 
administered because of its known bone marrow 
suppressive activity. At present, splenectomy is 
almost never necessary. Cyclosporine usually does 
not depress bone marrow function, and hyper-
splenism, if it exists prior to liver transplantation, 
will improve or disappear after a successful liver 
transplantation. 
Recipient hepatectomy is usually performed by 
dissecting the hUar structures and the vena cava 
above and below the liver, and by then cross-
clamping and dividing the various vessels just as the 
liver is removed. 18•25 However, in some cases, a 
safer way has been to transect the hilar structures 
first and the infrahepatic vena cava when all else is 
in readiness. Then, by pulling on clamps that are 
placed on the hepatic side of these structures, the 
liver is dissected free from below to above, ligating 
all tissues on the way. The vena cava above the liver 
remains intact as the stalk of the specimen until it 
is clamped just before the liver is removed.25 
During the implantation of the new liver, it is 
necessary to occlude the splanchnic and vena caval 
A 
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circulations. Most patients can survive this insult. 
In recent cases, venovenous bypass of these venous 
beds without heparinization has been used. This 
venovenous bypass system without hepa.rin has pro-
vided promising preliminary results. 
Completed orthotopic liver transplantation is 
shown in Figure 1. The usual order of anastomoses 
is as follows: (1) suprahepatic vena cava; (2) infra-
hepatic vena cava followed by a washout of high 
potassium preservation fluid with Ringer's lactate 
solution through the portal vein; (3) portal vein, 
after which the liver is partially vascularized; (4) 
hepatic artery, and (5) biliary system. 
End-to-end choledochocholedochostomy with 
T-tube or straight tube stent has been our choice 
when both donor and recipient bile ducts are suit-
able for anastomoses (Fig. I-A). If the recipient bile 
duct is diseased or absent end-to-side choledocho-
jejunostomy in Roux-en-Y is chosen (Fig. I-B). The 
gallbladder is not used for biliary reconstruction 
except for unusual circumstances.21.24.25 
IMMUNOSUPPRESSION WITH 
CYCLOSPORINE 
Cyclosporine is administered before liver 
grafting in an oral dose of 17.5 mg/kg or an intra-
B 
FIG. 1. Completed orthotopic liver transplantation. A: Biliary tract reconstruction with choledochocholedochostomy. B: Biliary 
tract reconstruction with choledochojajunostomy in Roux-en-Y. (Reproduced with permission from Starzl at a1.21 ) 
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venous dose of S mg/kg. Soon after the operation, 
cyclosporine is given intravenously as a dose of 2 
mg/kg every 8 hours. When the patient can resume 
oral intake, 17.S mg/kg of cyclosporine in two 
divided doses is given in addition to the intravenous 
doses. Intravenous cyclosporine is gradually with-
drawn, depending upon the renal function, the 
blood level of cyclosporine, and graft function. 
Maintenance dosage of cyclosporine is adjusted, 
mainly based on the nephrotoxicity of the drug,12 
and usually it is in the 10 mg/kg/day range at 1 
month and 8 mg/kg at 6 months. Children seem to 
tolerate the drug better than adults, and their main-
tenance dose of cyclosporine is higher than that of 
adults. 
Steroids are necessary in addition to cyclo-
sporine to achieve adequate immunosuppression, 
but the dose is much less than that required in com-
bination with azathioprine. 19•23 ,26 One gram of 
methylprednisolone is administered intravenously 
soon after revascularization of the liver graft. Post-
operatively, methylprednisolone or prednisone is 
given to adults in dosages of 200 mg/day on the 
first day, and the dose is decreased by 40 mg daily 
until the daily maintenance dose of 20 mg is reached 
on the sixth day. Further reduction of the steroid 
dose depends upon graft function. Usually the pa-
tient is discharged with a daily maintenance dose of 
prednisone of less than IS mg 1 to 2 months after 
transplantation. Initial and maintenance doses of 
steroids are reduced in infants and children. 
If rejection occurs in spite of the immunosup-
pressive therapy outlined, boluses of intravenous 
steroid therapy (1 gm of hydrocortisone or methyl-
prednisolone) and/or a recycle of the original S-day 
burst of prednisone therapy are given immediately. 
Although cyciosporine does not permit much dose 
maneuverability, it is sometimes possible to increase 
the dose in spite of the risk of nephrotoxicity. 
INDICATIONS FOR LIVER 
TRANSPLANTATION 
Indications for liver transplantation in 40 pedi-
atric patients and in 60 adults are listed in Tables 2 
and 3. The indications for one-half of the pediatric 
liver transplantations were biliary atresia or hypo-
plasia. All of the children with biliary atresia had 
had porticoenterostomy (Kasai operation). The 
three most common indications for adults were 
chronic aggressive hepatitis with cirrhosis, primary 
biliary cirrhosis, and primary liver malignancy. 
Three of the 21 patients (3 children and 18 
adults) with chronic aggressive hepatitis were posi-
tive for hepatitis B surface antigen (HBsAg). All 
three patients were treated with hepatitis B hyper-
TABLE 2. Indications for Transplantation in Pediatric 
Patients (s 18 Yearsl Among 100 Consecutive 
Patients Treated with Cyclosporine·Steroid Therapy 
Liver Pathology 
Biliary atresia * 
Alpha-I-antitrypsin deficiencyt 
Chronic aggressive hepatitis 
Byler's diseaset 
Secondary biliary cirrhosis§ 
Budd-Chiari syndrome 
Neonatal hepatitis 
Subacute Wilson's diseaset 
qyrosinemia~ 
Type I glycogen storage diseaset 
Sea·blue histiocyte syndromet 
Cellular inflammatory pseudotumor 
Total 
*Two had Alagille's syndrome. 
No. 
20 
6 
3 
3 
I 
40 
tlnborn errors of metabolism. The children with tyrosinemia and 
sea-blue histiocyte syndrome had incidental hepatomas in their 
cirrhotic livers. 
tDiagnosis equivocal in one case. 
§Choledochal cyst with multiple operations. 
TABLE 3. Indications for Transplantation in Adult 
Patients (2: 19 Yearsl Among 100 Consecutive 
Patients Treated with Cyclosporine·Steroid Therapy 
Liver Pathology 
Chronic aggressive hepatitis 
Primary biliary cirrhosis 
Primary liver malignancy· 
Sclerosing cholangitis 
Secondary biliary cirrhosist 
Budd-Chiari syndrome 
Alpha-I-antitrypsin deficiency 
Alcoholic cirrhosis 
Adenomatosis* 
Total 
No. 
18 
12 
II 
7 
4 
3 
2 
2 
I 
60 
*One patient in each group had previous (1 and 4 Vz years earlier) 
right hepatic trisegmentectomy. At transplantation. the regener-
ated left lateral segment was replaced with a whole liver. 
tlncluding two trauma and one each of Caroli's disease and 
choledochal cyst. 
immune globulin immediately after liver transplan-
tation. Despite this, all three patients, after brief 
periods of negative HBsAg, became HBsAg positive 
and developed chronic active hepatitis.21 None of 
the 12 patients with primary biliary cirrhosis have 
developed clinical and histologic evidence of recur-
rence in spite of the reappearance of antimitochon-
drial antibodies in two patients.21 
Thirteen patients with primary liver malignancy 
(2 children with incidental hepatoma and 11 adults) 
received liver transplantation. Three adults died 
from recurrent tumor after 9 months (Klatskin 
tumor), 12 months (cholangiocarcinoma), and 32 
months (fibrolamellar hepatocellular carcinoma). 
Seven of the 13 patients are alive free of tumor 6 to 
21 months after transplantation. Our previous ex-
178 
periencell~rKO4KOR indicates that malignant tumor 
will recur in most cases, if the malignancy is known 
before transplantation, but that if the malignancy is 
an incidenUlI finding of pathologic examination or 
the malignancy is absolutely confined to the liver, 
cure can be achieved by total hepatectomy and liver 
replacement (orthotopic liver transplantation). 
Selection of the patients with primary liver malig-
nancy is extremely difficult. 
CAUSES OF DEATH 
It is often difficult to categorize the cause of 
death after liver transplantation, because most of 
the deaths are due to multiple organ failure. How-
ever, the causes of death within a year after liver 
transplantation among 100 consecutive patients 
with cyclosporine-steriod therapy were classified to 
the best of our knowledge as shown in Table 4. 
Seven patients died during or soon after the 
operation. Three of the seven had abnormally small 
portal veins and attempts to obtain adequate portal 
flow from the confluence of the splenic and superior 
mesenteric veins resulted in fatal hemorrhage. Two 
patients had had portacaval anastomoses and satis-
factory portal vein anastomoses could not be 
achieved. One patient had had mUltiple surgeries 
for a shotgun wound of the liver, and a combina-
tion of biliary fistula, abscess, and dense scar tissue 
made the operation unsuccessful. One child with 
biliary atresia had hypotension and cardiac arrest 
during the cross-clamping of the suprahepatic and 
infrahepatic vena cava. Anastomoses were com-
pleted, but the patient was brain dead at the end of 
the operation. Postmortem examination revealed 
the absence of superior vena cava and collateral 
veins from the upper body draining into the inferior 
vena cava below the renal veins. This patient died 
from brain congestion during the cross-clamping of 
the inferior vena cava. 
Eight patients died from various surgical 
technical complications several days to 3 months 
after liver transplantation. Two children died from 
TABLE 4. Main Causes of Deaths Within a Year 
Among 100 Consecutive Liver Recipients Treated 
with Cyclosporine-Steroid Therapy 
Major Causes No. 
Intra- and perioperative death 
Surgical technical complications 
Unsatisfactory liver graft 
Graft rejection 
Infection 
Recurrent hepatitis B 
Recurrent malignancy 
Other* 
"Graft hypoxia due to marked pulmonary arteriovenous shunt. 
7 
8 
5 
10 
7 
2 
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hepatic artery thrombosis, and two others died from 
both hepatic artery and portal vein thrombosis. All 
four of these children had abnormal hepatic arteries 
and/or hypoplastic portal veins and two of them 
had venous homografts, one for the hepatic artery 
and another for the portal vein, to establish satis-
factory inflow to the liver graft. 
One child had had portal vein thrombosis after 
a previous splenectomy, and the graft portal vein 
inflow was substituted by portacaval transposition. 
However, the portal vein was thrombosed several 
days later and the child died from liver failure. An-
other child with biliary atresia did not have an 
inferior vena cava and the hepatic vein, which was 
anatomosed to the right atrium, was twisted and 
thrombosed after transplantation. A third child 
developed a leak from choledochojejunostomy and 
an abscess formed at the hepatic hilum. An attempt 
to drain the abscess and to reconstruct the biliary 
system led to fatal hemorrhage from the portal vein. 
Surgical technical complications have been less 
common in adults than in children. One adult 
patient developed hematobilia due to mycotic 
aneurysm of the hepatic artery. The hepatic artery 
was replaced with a homograft, but ruptured a week 
later due to infection. This patient died suddenly 
from exanguination. 
Five patients died after being given unsatisfac-
tory liver grafts that had been damaged before or at 
the time of organ harvest. Four of the five poor 
grafts were the first four liver transplantations in 
Pittsburgh. Since then, procedures of multiple 
organ procurement in cooperation with other trans-
plant teams have been standardized as described 
previously. 
Ten patients died from liver failure due to 
acute and chronic rejection. However, most of these 
patients developed serious infectious complications 
during the aggressive treatment for rejection with 
high doses of steroids. 
Seven patients died from infectious complica-
tions in the abdomen (3), lungs (3), and throat 
(leading to asphyxiation, I). 
Two patients died with liver failure due to re-
current or persistent chronic aggressive (HBsAg 
positive) hepatitis after liver transplantation. One of 
them also developed pulmonary sepsis and another 
necrotizing pancreatitis at the end of their lives. 
One patient died from recurrent Klatskin tumor 
9 months after liver transplantation. Another pa-
tient with alpha-I-antitrypsin deficiency disease died 
from graft failure due to persistent hypoxia caused 
by pulmonary arteriovenous shunts, which did not 
close despite a successful liver transplantation. 
For further improvement in survival, it is 
worthwhile to note that at least ten early deaths 
could have been avoided if the patients with abnor-
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malities of the portal vein. hepatic artery, or vena 
cava had not been accepted as liver transplant can-
didates. However. this kind of surgical technical 
challenge may be justified. because a similar number 
of patients with these anatomic disadvantages have 
been saved by liver transplantation. 
IMPROVED SURVIVAL 
The actuarial survival calculated from the 67 
consecutive cases treated with cyclosporine-steroid 
therapy since 1980 were compared with the actual 
survival of 170 consecutive cases treated with 
azathioprine-steroid and/or antilymphocyte globulin 
between 1963 and 1979 (Fig. 2). The survival after 
liver transplantation obtained at Cambridge-King's 
College, England. was calculated from their pub-
lished reports3.6,7 and is also shown in Figure 2 for 
comparison. 
Since the introduction of cyclosporine-steroid 
therapy to our standard immunosuppression regi-
men, the survival after liver transplantation has 
doubled. Although long-term survival with cyclo-
sporine-steroid therapy is limited to 3 years, current 
data suggest that a 5-year survival of 50070 will be 
achieved in the near future. 
CONCLUSIONS 
The number of human orthotopic liver trans-
plantations is rapidly approaching 500, of which 
approximately 90% have been performed by two 
groups: Starzl and associates at Denver and Pitts-
burgh, and Caine et al at Cambridge. The combina-
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FIG. 2. The actuarial survival of patients with cyclosporine 
and low-dose steroids compered with that obtained with 
conventional azathioprine, steroids, and antilymphocyte 
globulin by the authors and that by the workers at Cam-
bridge. The data for the Cambridge curve were obtained from 
published reports. (Reprinted with permission from Caine et aI.3.7) 
tion of a successful surgical technique and the im-
proved immunosuppression offered by cyclosporine 
give every promise of providing a 50% 5-year sur-
vival in appropriately selected patients. These exper-
iences indicate that the time has come for the crea-
tion of additional centers capable of performing 
this procedure. 
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